Celldex has key catalysts in 2023, says Cantor Fitzgerald

Cantor Fitzgerald analyst Kristen Kluska reiterates an Overweight rating on Celldex with a $55 price target as part of her "New Year’s Countdown" of 10 stocks with 2023 catalysts that should be on investors’ radar. Celldex’s barzolvolimab has been one of the most followed clinical candidates in the space, and 2023 should bring updates across multiple indications, potentially starting in February, Kluska tells investors in a research note. She believes investors see opportunity for barzolvolimab beyond chronic spontaneous urticaria and chronic inducible urticaria.